Georgia-based Galectin Therapeutics, Inc. (NASDAQ: GALT) is a biotechnology company focused on discovery and development. The company applies its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates are based on its unique carbohydrate technology targeting galectin proteins, which are key mediators of biologic and pathologic function. Galectin is especially pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. For more information, visit the company’s website at www.galectintherapeutics.com.